Soleno Therapeutics (SLNO)

• Market cap: $3.7B
• 1 day: 4.66%
• 5 days: 2.07%
• 1 month: -18.35%
• 3 months: -8.72%
• 6 months: 54.35%
• Year to date: 52.29%
• 1 year: 50.90%
• 5 years: 130.88%
• 10 years: -50.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

Employees: 133

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

84% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 57

41% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 34

21% more capital invested

Capital invested by funds: $3.9B [Q1] → $4.72B (+$817M) [Q2]

6% more funds holding

Funds holding: 216 [Q1] → 228 (+12) [Q2]

10% more call options, than puts

Call options by funds: $130M | Put options by funds: $118M

7.23% less ownership

Funds ownership: 118.99% [Q1] → 111.76% (-7.23%) [Q2]

16% less funds holding in top 10

Funds holding in top 10: 19 [Q1] → 16 (-3) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $106 52% upside
• Avg. target: $114 64% upside
• High target: $123 77% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Wells Fargo Derek Archila	77% upside $123	Overweight Initiated	20 Aug 2025
HC Wainwright & Co. Raghuram Selvaraju	58% upside $110	Buy Maintained	18 Aug 2025
Guggenheim Debjit Chattopadhyay	52% upside $106	Buy Maintained	7 Aug 2025
Oppenheimer Leland Gershell	58% upside $110	Outperform Maintained	7 Aug 2025
Baird Brian Skorney	74% upside $121	Outperform Maintained	11 Jul 2025